Weekly round-up: With an innovative cancer tie-up and a €90m Series A financing, Optimum’s clients kick off 2025 in style

/in

Poolbeg Pharma plc and HOOKIPA Pharma Inc. kicked off 2025 in a positive fashion, entering into non-binding discussions for an all-share acquisition by HOOKIPA of Poolbeg The aim is to create a strong clinical-stage biopharmaceutical company focused on developing and commercialising innovative medicines for critical unmet medical needs, with a special focus on next-generation immunotherapies […]

Read more

Hot topic: Will you live longer than your parents… or not?

/in

Not long ago, it was taken as a given that we’d live longer than our parents – just as most of them lived longer and healthier lives than their own.  But something strange has happened in the last 15 years or so.  Increases in life expectancy have stalled, and there are signs it might even […]

Read more

The must attend healthcare conferences in Winter/Spring 2025

/in

Where has the time gone? We are now in 2025, and industry events are quickly approaching.   If you are still gathering your thoughts on how best to maximise your events calendar this year, allow us to flag some of the ‘must-attend’ Healthcare conferences of Winter/Spring 2025.   January is for JPM   The 43rd JPM Annual Healthcare Conference: 13th-16th January, […]

Read more

Optimum’s clients shine in major mergers, approvals and awards in ‘24

/in

2024 has been a phenomenal year for Optimum and its clients, with some spectacular successes both in and out of the clinic.  Here are some of the highlights from a year that saw the life sciences industry get back on track after some challenging times.  M&A Deals  There was great news for Calliditas Therapeutics, one […]

Read more

Optimum showcases cutting-edge life sciences R&D in ‘24

/in

Optimum’s clients pushed on with their vital research in 2024, from preclinical studies to cutting-edge oncology clinical trials.  Biocomposites announced two new Phase II clinical trials of Stimulan VG, a calcium matrix antibiotic carrier mixed with vancomycin and gentamicin, to take place in the U.S. BLADE-VG2 trial will evaluate the safety and efficacy of STIMULAN […]

Read more